ログイン
言語:

WEKO3

  • トップ
  • ランキング
To
lat lon distance
To

Field does not validate



インデックスリンク

インデックスツリー

メールアドレスを入力してください。

WEKO

One fine body…

WEKO

One fine body…

アイテム

  1. 学内発行雑誌
  2. The Showa University journal of medical sciences
  3. Vol.30(2018)
  4. No.2

Indirect Comparison of Dupilumab and Mepolizumab Treatments for Uncontrolled Eosinophilic Asthma-Bayesian Analysis of Randomized Controlled Trials-

https://showa.repo.nii.ac.jp/records/467
https://showa.repo.nii.ac.jp/records/467
864cd4f6-1219-4ef9-b8e6-a1e7fc2c4771
名前 / ファイル ライセンス アクション
S30_189.pdf S30_189.pdf (434.5 kB)
Item type 学内発行雑誌 / Departmental Bulletin Paper(1)
公開日 2018-09-03
タイトル
タイトル Indirect Comparison of Dupilumab and Mepolizumab Treatments for Uncontrolled Eosinophilic Asthma-Bayesian Analysis of Randomized Controlled Trials-
言語
言語 eng
資源タイプ
資源タイプ departmental bulletin paper
著者 ANDO, Koichi

× ANDO, Koichi

ANDO, Koichi

Search repository
TANAKA, Akihiko

× TANAKA, Akihiko

TANAKA, Akihiko

Search repository
MIKUNI, Hatsuko

× MIKUNI, Hatsuko

MIKUNI, Hatsuko

Search repository
KAWAHARA, Tomoko

× KAWAHARA, Tomoko

KAWAHARA, Tomoko

Search repository
KUWAHARA, Naota

× KUWAHARA, Naota

KUWAHARA, Naota

Search repository
MANABE, Ryo

× MANABE, Ryo

MANABE, Ryo

Search repository
JINNO, Megumi

× JINNO, Megumi

JINNO, Megumi

Search repository
MIYATA, Yoshito

× MIYATA, Yoshito

MIYATA, Yoshito

Search repository
HIRAI, Kuniaki

× HIRAI, Kuniaki

HIRAI, Kuniaki

Search repository
OHNISHI, Tsukasa

× OHNISHI, Tsukasa

OHNISHI, Tsukasa

Search repository
INOUE, Shin

× INOUE, Shin

INOUE, Shin

Search repository
SAGARA, Hironori

× SAGARA, Hironori

SAGARA, Hironori

Search repository
書誌情報 The Showa University journal of medical sciences

巻 30, 号 2, p. 189-196, 発行日 2018-06
抄録
内容記述タイプ Abstract
内容記述 The efficacy and safety of dupilumab, a humanized interleukin (IL)-4 receptor alfa monoclonal antibody (mAb) that inhibits the signaling of the type 2 cytokines IL-4 and IL-13, for the treatment of uncontrolled eosinophilic asthma remains to be fully characterized, particularly in comparison to other therapeutic mAbs. Therefore, we conducted a meta-analysis of randomized controlled trials (RCTs) to indirectly compare the efficacy and safety of dupilumab with those of mepolizumab, a humanized anti-IL-5 mAb, in patients with uncontrolled eosinophilic asthma. Comparisons were made using the Bayesian statistical method. This meta-analysis complies with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Six RCTs were eligible for this study: two RCTs focused on dupilumab and four on mepolizumab. The primary efficacy outcome was a change in the forced expiratory volume at 1.0 second (FEV1.0), and the primary safety outcome was the incidence of severe adverse effects (SAE). The mean difference in changes in the FEV1.0 following treatment with dupilumab versus mepolizumab was 0.133 (95% CI, 0.016-0.252). There was no significant difference between these two agents in the incidence of SAE (OR, 1.99; 95% CI, 0.19-11.16). These results strongly indicate that dupilumab is more effective than mepolizumab and is generally well-tolerated in patients with uncontrolled eosinophilic asthma.
DOI
関連識別子 10.15369/sujms.30.189
出版者
出版者 Showa University Society
ISSN
収録物識別子 0915-6380
出版タイプ
出版タイプ VoR
戻る
0
views
See details
Views

Versions

Ver.1 2023-05-15 12:46:14.897613
Show All versions

Share

Mendeley Twitter Facebook Print Addthis

Cite as

エクスポート

OAI-PMH
  • OAI-PMH JPCOAR 2.0
  • OAI-PMH JPCOAR 1.0
  • OAI-PMH DublinCore
  • OAI-PMH DDI
Other Formats
  • JSON
  • BIBTEX

Confirm


Powered by WEKO3


Powered by WEKO3